Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) ...
The drugs up for price negotiations include cancer and diabetes drugs, as well as medications for Crohn's disease, ulcerative colitis and rheumatoid arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results